TNYA Latest News, Press Relases and Analysis

All

Press Releases

3 days ago - By: Chartmill - Mentions: FEIM CGC TLRY YCBD ...

Which stocks are experiencing notable movement on Friday?

3 days ago - By: Chartmill - Mentions: FEIM DXLG CGC TLRY ...

Let's take a look at the stocks that are in motion in today's session.

3 days ago - By: Chartmill - Mentions: DXLG CGC TLRY YCBD ...

There are notable gap-ups and gap-downs in today's session.

3 days ago - By: Chartmill - Mentions: NX PRPH DXLG TLRY ...

Wondering what's happening in today's pre-market session?

4 days ago - By: Tenaya Therapeutics, Inc.

Tenaya Therapeutics Announces Pricing of Public Offering

4 days ago - By: Chartmill - Mentions: CEP LULU NX MITK ...

Stay updated with the stocks that are on the move in today's after-hours session.

4 days ago - By: Tenaya Therapeutics, Inc.

Tenaya Therapeutics Announces Proposed Public Offering

4 days ago - By: Tenaya Therapeutics, Inc.

Tenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults with PKP2-associated ARVC

4 days ago - By: Tenaya Therapeutics, Inc.

Tenaya Therapeutics Announces Rapid Resolution and Lifting of Clinical Hold for MyPEAK-1™ Phase 1b/2a Clinical Trial of TN-201 Gene Therapy

13 days ago - By: Chartmill - Mentions: NCT AEO ACHC CTW ...

Which stocks are moving after the closing bell on Tuesday?

a month ago - By: Tenaya Therapeutics, Inc.

Tenaya Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

a month ago - By: Tenaya Therapeutics, Inc.

Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAK™-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

a month ago - By: Tenaya Therapeutics, Inc.

Tenaya Therapeutics Announces New Clinical Data for TN-201 Gene Therapy will be Featured in Late-Breaking Presentation at the American Heart Association Scientific Sessions 2025

2 months ago - By: Tenaya Therapeutics, Inc.

Tenaya Therapeutics to Participate in H.C. Wainwright Genetic Medicines Virtual Conference

2 months ago - By: Tenaya Therapeutics, Inc.

Tenaya Therapeutics to Participate in Upcoming October Investor Conferences

3 months ago - By: Tenaya Therapeutics, Inc.

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

3 months ago - By: Benzinga - Mentions: IFRX ALEC RNXT

Top 4 Biotech Stocks Set For A Breakout: Momentum Scores Surge

3 months ago - By: Tenaya Therapeutics, Inc.

Tenaya Therapeutics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

4 months ago - By: Tenaya Therapeutics, Inc.

Tenaya Therapeutics Presents Interim Data from MyClimb™ Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Society of Cardiology Congress 2025

4 months ago - By: Tenaya Therapeutics, Inc.

Tenaya Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference

4 months ago - By: The Motley Fool

Tenaya (TNYA) Q2 Loss Narrows 59%

4 months ago - By: Tenaya Therapeutics, Inc.

Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

5 months ago - By: Tenaya Therapeutics, Inc.

Tenaya Receives Positive Safety Reviews from Independent DSMBs to Advance Both TN-201 and TN-401 Gene Therapy Clinical Trials as Designed

7 months ago - By: Tenaya Therapeutics, Inc.

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

7 months ago - By: Tenaya Therapeutics, Inc.

Tenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual Meeting

8 months ago - By: Tenaya Therapeutics, Inc.

Tenaya Therapeutics Presents Interim Data from RIDGE™ Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm 2025

9 months ago - By: Tenaya Therapeutics, Inc.

Tenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting

9 months ago - By: Yahoo Finance

Is Tenaya Therapeutics, Inc. (TNYA) the Cheapest Stock Insiders Are Buying In March?

9 months ago - By: Tenaya Therapeutics, Inc.

Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models

9 months ago - By: Tenaya Therapeutics, Inc.

Tenaya Therapeutics Announces Late Breaker and New Data Presentations at the American College of Cardiology’s Annual Scientific Session

9 months ago - By: Stocktwits - Mentions: MLYS SWTX CSCI MGX

Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last Week

9 months ago - By: Tenaya Therapeutics, Inc.

TENAYA THERAPEUTICS INC (TNYA) Stock News

TNYA Latest News, Press Relases and Analysis

Which stocks are experiencing notable movement on Friday?

Let's take a look at the stocks that are in motion in today's session.

There are notable gap-ups and gap-downs in today's session.

Wondering what's happening in today's pre-market session?

Tenaya Therapeutics Announces Pricing of Public Offering

Stay updated with the stocks that are on the move in today's after-hours session.

Tenaya Therapeutics Announces Proposed Public Offering

Tenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults with PKP2-associated ARVC

Tenaya Therapeutics Announces Rapid Resolution and Lifting of Clinical Hold for MyPEAK-1™ Phase 1b/2a Clinical Trial of TN-201 Gene Therapy

Which stocks are moving after the closing bell on Tuesday?

Tenaya Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAK™-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

Tenaya Therapeutics Announces New Clinical Data for TN-201 Gene Therapy will be Featured in Late-Breaking Presentation at the American Heart Association Scientific Sessions 2025

Tenaya Therapeutics to Participate in H.C. Wainwright Genetic Medicines Virtual Conference

Tenaya Therapeutics to Participate in Upcoming October Investor Conferences

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Top 4 Biotech Stocks Set For A Breakout: Momentum Scores Surge

Tenaya Therapeutics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Tenaya Therapeutics Presents Interim Data from MyClimb™ Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Society of Cardiology Congress 2025

Tenaya Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference

Tenaya (TNYA) Q2 Loss Narrows 59%

Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Tenaya Receives Positive Safety Reviews from Independent DSMBs to Advance Both TN-201 and TN-401 Gene Therapy Clinical Trials as Designed

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Tenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual Meeting

Tenaya Therapeutics Presents Interim Data from RIDGE™ Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm 2025

Tenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting

Is Tenaya Therapeutics, Inc. (TNYA) the Cheapest Stock Insiders Are Buying In March?

Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models

Tenaya Therapeutics Announces Late Breaker and New Data Presentations at the American College of Cardiology’s Annual Scientific Session

Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last Week

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update